Document is current

Any future updates will be listed below

398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.398

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark